Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2009
10/28/2009CN101564441A Apoplexy rejuvenation preparation and preparation method thereof
10/28/2009CN101564438A Application of Chinese medicinal composition in preparation of medicament for treating acute severe brain injury
10/28/2009CN101564423A Medicament for treating cardiovascular and cerebrovascular diseases and preparation method thereof
10/28/2009CN101564413A Storax preparation of coronary disease and preparation method thereof
10/28/2009CN101564394A Pharmaceutical composition containing ivabradine and trimetazidine
10/28/2009CN101564388A Composition for Danshensu and danshinolic acid B and use thereof
10/28/2009CN101564184A Maror and chrysanthemum beverage for reducing blood fat and weight
10/28/2009CN101564159A Food for reducing hypertension and diabetes and preparation method thereof
10/28/2009CN101564077A Health tea for strengthening heart and replenishing qi of mid-aged and old people
10/28/2009CN100554270C Method for preparing dehydrogenated cavidine, dehydrogenated apocavidine and combination
10/28/2009CN100554268C Multicyclic compounds and the use as inhibitors of PARP, VEGFR2 and MLK3 enzymes
10/28/2009CN100554267C Muscle relaxation accelerator and therapeutic agent for muscular tissue diseases such as muscle relaxation failure
10/28/2009CN100554259C 2-benzo(C) foroxone compound, its production and use
10/28/2009CN100554253C Process for synthesizing lacidipine of antihypertensive drugs
10/28/2009CN100553677C Drugs for treating vascular diseases
10/28/2009CN100553650C Application of pharmaceutical composition in the process for preparing medicine to counteract aspirin resisting medicine
10/28/2009CN100553637C Hormone composition
10/28/2009CN100553631C Pharmaceutical uses of 4-fluoro-N-(1,2- hydrindenl-2-yl) benzamide
10/28/2009CN100553620C Medication for treating obstruction of qi in the chest
10/28/2009CN100553619C Medication for treating coronary heart disease and angina
10/28/2009CN100553618C Medication for treating toothache
10/28/2009CN100553617C Medicine for treating chest stuffiness and pains
10/28/2009CN100553615C Medication for treating cardiovascular and cerebrovascular diseases
10/28/2009CN100553614C Preparation method of quickly disintegrating and dissolving solid medicine composition for oral cavity and its tablet
10/27/2009US7608718 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
10/27/2009US7608698 Muscular disorders; cardiovascular disorders; cell transformed with nucleic acid; culture product
10/27/2009US7608634 Substituted pyrrolines as kinase inhibitors
10/27/2009US7608628 Alkylsulphonamide quinolines
10/27/2009US7608577 Peptidyl ketones as inhibitors of DPIV
10/27/2009US7608284 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli
10/27/2009US7608253 end-capped polyethylene glycol carbamate derivatives useful as water-soluble pro-drugs; controll hydrolytic degradation of hydrogels; conjugate polymer drug for controlled release
10/27/2009CA2466724C Benzamide and heteroarylamide as p2x7 receptor antagonists
10/27/2009CA2437006C Aminotriazolopyridine derivatives as adenosine receptor ligands
10/27/2009CA2435426C Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof
10/27/2009CA2422210C Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
10/27/2009CA2421826C Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
10/27/2009CA2415966C Tetrahydro-heterocycloazepinyl pyrimidine derivatives
10/27/2009CA2414584C 7-hydroxyepiandrosterone having neuroprotective activity
10/27/2009CA2406044C Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
10/27/2009CA2381885C Isomeric fused pyrrolocarbazoles and isoindolones
10/27/2009CA2376355C N-heterocyclic derivatives as nos inhibitors
10/27/2009CA2365204C Lipoxin compounds and their use
10/27/2009CA2318145C Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
10/22/2009WO2009129508A1 Soluble epoxide hydrolase inhibitors
10/22/2009WO2009129408A2 Compositions and methods for treating pathologic angiogenesis and vascular permeability
10/22/2009WO2009129260A2 Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
10/22/2009WO2009129191A1 Polymorphs of hydrochloride salt o5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b] indole-7-carboxamideand methods of use therefor
10/22/2009WO2009129163A2 Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
10/22/2009WO2009128738A2 Use of the extract of defatted seeds of primrose
10/22/2009WO2009128558A1 Activator for peroxisome proliferator-activated receptor
10/22/2009WO2009128520A1 Heterocyclic compound having inhibitory activity on p13k
10/22/2009WO2009128481A1 Nitrogenated 5-membered heterocyclic compound
10/22/2009WO2009128383A1 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUND
10/22/2009WO2009127949A1 4- [3- (aryloxy) benzylidene] -3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
10/22/2009WO2009127948A1 4- [3- (aryloxy) benzylidene] -3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
10/22/2009WO2009127946A1 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors
10/22/2009WO2009127944A1 Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
10/22/2009WO2009127943A1 Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
10/22/2009WO2009127922A2 Pharmaceutical formulation for treating cardiovascular disease
10/22/2009WO2009127768A1 Use of liver growth factor (lgf) as a neural tissue regenerator
10/22/2009WO2009127398A2 Conjugated linoleic acid derivatives
10/22/2009WO2009127338A1 Oxo-heterocyclic substituted carboxylic acid derivates and the use thereof
10/22/2009WO2009127251A1 Combinations comprising a renin inhibitor
10/22/2009WO2009093264A3 Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc.
10/22/2009WO2009046827A3 Use of growth hormone-releasing factor and/or mage-3 antigen (271-279) as therapeutic agents
10/22/2009WO2009043518A3 Use of a combination of cart peptides as a therapeutic agent
10/22/2009WO2009040050A3 Use of calcitonin as anti-angiogenic agent
10/22/2009WO2009040036A3 Use of a galanin peptide as a therapeutic agent
10/22/2009WO2009039982A3 Use of gip alone or in combination with dynorphin b as a therapeutic agent
10/22/2009WO2009039972A3 Use of muramyl dipeptide (mdp) as a therapeutic agent
10/22/2009WO2009037191A3 Use of g-csf for the treatment of stroke
10/22/2009WO2009033810A3 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection
10/22/2009WO2009000907A3 Combination of picotamide with nafronyl
10/22/2009WO2008089103A8 Targeting ncca-atp channel for organ protection following ischemic episode
10/22/2009US20090265798 Desaturase genes and uses thereof
10/22/2009US20090264535 Liquid drug formulation
10/22/2009US20090264506 Delivery of polynucleotide agents to the central nervous system
10/22/2009US20090264501 Methods and Compositions to Inhibit P2x7 Receptor Expression
10/22/2009US20090264468 Methods for treating a disease in which Rho kinase is involved
10/22/2009US20090264453 Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
10/22/2009US20090264426 Bicyclic aromatic substituted pyridone derivative
10/22/2009US20090264424 Vanilloid receptor ligands and their use in treatments
10/22/2009US20090264420 Organic compounds
10/22/2009US20090264370 Polypeptides homologous to vegf and bmp1
10/22/2009US20090264369 Methods for reducing cd36 expression
10/22/2009US20090264364 Genes implicated in the regulation of angiogenesis, pharmaceutical preparations containing them and their applications
10/22/2009US20090264363 Leucine-Rich Peptide Compositions and Methods for Isolation
10/22/2009US20090264361 Identification of a family of secreted proteins in vascular endothelium
10/22/2009US20090264357 NOVEL AGENT THAT INHIBITS ANGIOGENESIS AND METASTASIS TARGETING mTOR SIGNALING PATHWAY
10/22/2009US20090264352 Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
10/22/2009US20090264339 Heterocyclic Compounds
10/22/2009US20090263847 Lsr receptor, its activity, its cloning and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications
10/22/2009US20090263477 Salts of fenofibric acid and pharmaceutical formulations thereof
10/22/2009US20090263472 Endothelin receptor antagonist derivatives
10/22/2009US20090263466 Herbal composition for treatment of hyperlipidemia and the inhibition of myocardial infarction
10/22/2009US20090263462 Methods for Treating Conditions Such as Dystonia and Post-Stroke Spasticity with Clonidine
10/22/2009US20090263460 Medical devices and methods including polymers having biologically active agents therein
10/22/2009US20090263457 Block copolymer comprising at least one polyester block and a poly(ethylene glycol) block
10/22/2009US20090263389 Use of TGF-Beta Antagonists to Treat or to Prevent Chronic Transplant Rejection
10/22/2009US20090263373 Non-neurotoxic plasminogen activating factors for treating of stroke
1 ... 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 ... 1595